Kirkland Advises Clene Nanomedicine on Successful Closing of Merger with Tottenham

Kirkland & Ellis represented Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, on the successful closing of its merger with Tottenham Acquisition I Limited, a special purpose acquisition company. Proceeds from the transaction were approximately $31.9 million, which included funds held in Tottenham’s trust account and a concurrent private investment in public equity financing led by existing shareholders of Clene. The combined company will operate under the name Clene Inc. and commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020. 

Read more in Clene’s press release

The Kirkland team was led by transactional partners David Zhang, Ben James and James Hu, and included tax partners Dean Shulman and Vivek Ratnam and executive compensation partner Michael Krasnovsky.